Céline Loriot
Affiliations: | Université Paris 5 |
Area:
PCC/PGL, SDHB, Malignancy, EMT, KRT19Google:
"Céline Loriot"Parents
Sign in to add mentor| Anne-Paule Gimenez-Roqueplo | grad student | 2014 | Université Paris 5 | |
| (Etude des mécanismes moléculaires et cellulaires responsables de la malignité des phéochromocytomes et des paragangliomes SDHB-dépendants) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Loriot C, Domingues M, Berger A, et al. (2015) Deciphering the molecular basis of invasiveness in Sdhb-deficient cells. Oncotarget |
| Castro-Vega LJ, Letouzé E, Burnichon N, et al. (2015) Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nature Communications. 6: 6044 |
| Hadoux J, Favier J, Scoazec JY, et al. (2014) SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. International Journal of Cancer. 135: 2711-20 |
| Letouzé E, Martinelli C, Loriot C, et al. (2013) SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell. 23: 739-52 |
| Burnichon N, Buffet A, Parfait B, et al. (2012) Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Human Molecular Genetics. 21: 5397-405 |
| Loriot C, Burnichon N, Gadessaud N, et al. (2012) Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations. The Journal of Clinical Endocrinology and Metabolism. 97: E954-62 |
| Hadoux J, Leboulleux S, Al Ghuzlan A, et al. (2012) Traitement par temozolomide des phéochromocytomes/paragangliomes métastatiques (PPM) progressifs : la faible expression de MGMT et la mutation SDHB prédisent l’efficacité Annales D'Endocrinologie. 73: 253-254 |
| Gratio V, Loriot C, Virca GD, et al. (2011) Kallikrein-related peptidase 14 acts on proteinase-activated receptor 2 to induce signaling pathway in colon cancer cells. The American Journal of Pathology. 179: 2625-36 |